Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

Events like one held Thursday at Fayetteville Town Center can affect how challenges surrounding schizophrenia and mental ...

Using a multi-strain probiotic formulation, researchers conducted a double-blind, randomized, placebo-controlled trial aimed at improving psychiatric and cognitive symptoms, intestinal permeability, ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

Schizophrenia is a serious mental disorder that affects around 1% of the world's population. Researchers of the University of ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

Explore the reality of schizophrenia by debunking seven myths and offering compassionate insights into this complex mental ...

Today, in 2025, I remember my four years homeless in Los Angeles, and am thankful for my recovery from schizophrenia.

Peptide antigen-associated IgG levels were significantly lower in drug-naïve patients with first episode psychosis compared to control individuals.

US biotech Intra-Cellular Therapies’ has claimed an FDA approval for schizophrenia therapy lumateperone setting up the launch of the drug as its first commercial product next year. The green ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the ...